Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin in multiple sclerosis
IRCT20210211050323N3Phase 2Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Apr 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rosuvastatin in multiple sclerosis (MS), sponsored by Hamadan University of Medical Sciences. Primary endpoints: cytochrome b-245 beta chain (CYBB) gene expression and Expanded Disability Status Scale (EDSS) score. Started Apr 2022; status: completed.
02
Drugs
rosuvastatin
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT20210211050323N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210211050323N3.